Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser, Stefan; Steg, Philippe; Oldgren, Jonas; Nickenig, Georg; Kiss, Robert; Ongen, Zeki; Navarro Estrada, Jose; Ophuis, Ton; Lip, Gregory; Nordaby, Matias; Kleine, Eva; ten Berg, Jurrien; Bhatt, Deepak; Cannon, Christopher

doi:10.1016/j.jcin.2019.05.050

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser S. H., Steg P. G., Oldgren J., Nickenig G., Kiss R. G., Ongen Z., ...Daha Fazla

JACC-CARDIOVASCULAR INTERVENTIONS, cilt.12, sa.16, ss.1553-1561, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 12 Sayı: 16
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jcin.2019.05.050
Dergi Adı: JACC-CARDIOVASCULAR INTERVENTIONS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1553-1561
İstanbul Üniversitesi Adresli: Evet

Özet

OBJECTIVES The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.